Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 28 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-2.64 Insider Own49.67% Shs Outstand18.88M Perf Week-1.79%
Market Cap80.35M Forward P/E- EPS next Y-1.29 Insider Trans0.00% Shs Float12.26M Perf Month18.71%
Income-53.68M PEG- EPS next Q-0.36 Inst Own21.69% Short Float0.16% Perf Quarter0.30%
Sales28.99M P/S2.77 EPS this Y27.53% Inst Trans-0.09% Short Ratio1.30 Perf Half Y94.12%
Book/sh-2.07 P/B- EPS next Y21.58% ROA-109.08% Short Interest0.02M Perf Year54.21%
Cash/sh0.52 P/C6.40 EPS next 5Y- ROE- 52W Range1.10 - 4.19 Perf YTD52.78%
Dividend Est.- P/FCF- EPS past 5Y-17.26% ROI- 52W High-21.23% Beta0.62
Dividend TTM- Quick Ratio0.55 Sales past 5Y-5.10% Gross Margin30.31% 52W Low199.97% ATR (14)0.26
Dividend Ex-Date- Current Ratio0.63 EPS Y/Y TTM-15.53% Oper. Margin-81.33% RSI (14)56.44 Volatility9.81% 8.45%
Employees54 Debt/Eq- Sales Y/Y TTM-42.86% Profit Margin-185.15% Recom1.00 Target Price5.00
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q-52.39% Payout- Rel Volume0.98 Prev Close3.25
Sales Surprise9.74% EPS Surprise-80.72% Sales Q/Q-48.70% EarningsMay 09 AMC Avg Volume14.92K Price3.30
SMA206.02% SMA506.73% SMA20035.87% Trades Volume14,609 Change1.54%
Date Action Analyst Rating Change Price Target Change
Nov-02-20Initiated Truist Buy $20
Nov-02-20Initiated Piper Sandler Overweight $20
Nov-02-20Initiated Cowen Outperform $20
Nov-02-20Initiated Cantor Fitzgerald Overweight $20
May-13-24 08:00AM
May-09-24 10:55PM
May-02-24 04:05PM
Apr-29-24 09:00AM
04:05PM Loading…
Apr-24-24 04:05PM
Mar-07-24 09:53PM
Feb-22-24 04:05PM
Feb-20-24 10:37AM
Jan-10-24 04:05PM
Dec-18-23 08:00AM
Nov-13-23 04:05PM
Nov-09-23 08:30AM
Nov-06-23 04:05PM
08:00AM Loading…
Oct-18-23 08:00AM
Sep-20-23 08:30AM
Sep-19-23 08:36AM
Sep-18-23 04:08PM
Sep-08-23 08:30AM
Sep-06-23 04:05PM
Aug-30-23 08:30AM
Aug-21-23 09:42AM
Aug-15-23 05:21AM
Aug-14-23 04:05PM
Jul-31-23 04:05PM
Jul-26-23 03:29PM
Jul-17-23 04:05PM
Jul-13-23 04:30PM
May-19-23 01:45PM
08:15AM Loading…
May-13-23 08:17AM
May-11-23 09:58AM
May-10-23 04:05PM
May-03-23 04:05PM
Apr-20-23 04:30PM
Apr-17-23 06:11AM
Apr-05-23 09:55AM
Mar-27-23 06:26AM
Mar-23-23 06:08AM
Mar-22-23 04:01PM
Mar-20-23 12:01PM
Mar-15-23 04:05PM
Feb-27-23 08:15AM
Jan-31-23 08:00AM
Jan-26-23 12:00PM
Jan-21-23 09:58AM
Jan-09-23 08:15AM
Dec-15-22 08:00AM
Dec-10-22 07:38AM
Dec-01-22 09:04AM
Nov-30-22 04:08PM
Nov-21-22 04:05PM
Nov-16-22 06:00AM
Nov-14-22 05:25PM
Nov-07-22 04:05PM
Oct-25-22 09:47AM
Oct-24-22 08:00AM
Oct-18-22 04:05PM
Oct-11-22 04:35PM
Aug-26-22 09:00AM
Aug-17-22 04:05PM
Aug-16-22 01:53PM
Aug-14-22 10:16AM
Aug-11-22 04:05PM
Aug-10-22 06:56PM
Aug-09-22 05:58PM
Jul-28-22 04:05PM
Jul-20-22 09:40AM
Jun-27-22 04:15AM
Jun-21-22 04:05PM
Jun-01-22 08:50AM
May-09-22 05:25PM
May-02-22 08:21AM
Apr-25-22 04:05PM
Apr-12-22 04:05PM
Apr-04-22 08:00AM
Mar-31-22 06:50PM
Mar-11-22 08:30AM
Mar-07-22 06:40AM
Mar-04-22 09:28AM
Mar-03-22 06:25PM
Feb-23-22 04:01PM
Feb-17-22 04:01PM
Feb-14-22 12:00PM
Jan-18-22 08:45AM
Jan-11-22 10:00AM
Dec-27-21 04:01PM
Elutia, Inc. operates as a biotechnology company. It develops biologic products to improve compatibility between medical devices and the patients who need them. The firm operates through the following segments: Device Protection, Women's Health, Orthobiologics and Cardiovascular. The Device Protection segment includes biological envelope that remodels into systematically connected, vascularized tissue for the long-term pocket protection of certain cardiac and neurostimulator implantable electronic vehicles. The Women's Health segment includes pre-hydrated, human acellular dermal matrix, or HADM, that is designed to enable rapid integration, cellular repopulation and rapid revascularization at the surgical site. The Orthobiologics segment includes a variety of viable matrices, produced with a proprietary process that is designed to protect and preserve native bone cells and reduce programmable cell death, for use in bone repair and fusion procedures. The Cardiovascular segment includes a portfolio of extracellular matrices that retain the natural composition of collagen, growth factors and proteins for use in vascular and cardiac repair and pericardial closure. The company was founded by Kevin L. Rakin and Charles Randal Mills on August 6, 2015 and is headquartered in Silver Spring, MD.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ferguson MatthewCHIEF FINANCIAL OFFICERMar 08 '24Option Exercise0.001,2880121,807Mar 14 04:43 PM